Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook - Novartis (NYSE:NVS)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Novartis AG (NYSE:NVS) has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44.
Net income reached $2.2 billion, an increase of 8% or 15% at constant currency rates, mainly driven by higher operating income, partly offset by the loss of Roche Holding (OTC:RHHBY) income.
Operating income was $2.85 billion, an increase of 18% from the prior year, mainly due to higher sales, increased productivity, and lower impairments, partly offset by higher R&D and M&S investments.
Net sales were $12.53 billion, increasing 1% or 5% at constant currency rates from the prior year, missing the consensus of $12.73 billion.
The increase was driven by volume growth of 11 percentage points, price erosion of 3 percentage points, and the negative impact of the generic competition of 3 percentage points.
Revenue from Entresto jumped 42% to $1.1 billion.
Core operating income at Sandoz returned to growth in the quarter with a gain of 21% to $538 million on a rebound in cold remedies.
Guidance: Looking ahead to FY22, Novartis still expects core operating income to grow mid-single digit. Sales are still expected to grow mid-single digit.
Price Action: NVS shares are up 0.51% at $90.90 during the premarket session on the last check Tuesday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!